Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Cann Group will increase the full capacity of its Mildura facility by 40 per cent
  • With the increased facility Cann is expecting to generate $220 million to $280 million in annual revenue
  • Completion of the facility is expected to be finished by the end of 2020

Cann Group will increase the full capacity of its Mildura facility by 40 per cent.

Cann is a world-class business focused on breeding, cultivating and manufacturing medicinal hemp for sale and use in Australia. It has established research and cultivation facilities in Melbourne.

The company has worked with construction partners to improve space utilisation and efficiencies with the plant production system. The facility will now produce 70,000kg of dry flower per annum.

With the increased facility Cann is expecting to generate $220 million to $280 million in annual revenue.

CEO Peter Crock says the decision to increase the facility was in line with the company’s goals.

“We’ve previously stated our intention to set up at scale, and the opportunity to amend the plans for the Mildura facility significantly boosts our production capacity; improves our production efficiencies and results in greater revenue potential from the site,” he said.

Mildura is a city located northwest in Victoria, Australia.

Cann has received support from its major shareholder and strategic partner, Aurora Cannabis.

“Specialised components from the Netherlands continue to arrive at the site and construction is progressing well. We are looking forward to pushing on with this major expansion and keeping the market informed of our progress over the next year,” Peter added.

The cultivation and production of medicinal hemp at Mildura facility will serve both domestic and international markets after Cann announced its five-year off-take agreement with Aurora earlier this year.

Completion of the facility is expected to be finished by the end of 2020. Siteworks have been completed and construction is now underway.

CAN by the numbers
More From The Market Herald
Heramed (ASX:HMD) - CEO and Co Founder, David Groberman

" HeraMED (ASX:HMD) raises $2.39m via convertible note placement

HeraMED (HMD) has raised roughly $2.39 million through a convertible note placement.
NeuroScientific Biopharmaceuticals (ASX:NSB) - MD and CEO, Matthew Liddelow

" NeuroScientific Biopharmaceuticals (ASX:NSB) completes safety pharmacology studies

NeuroScientific Biopharmaceuticals (NSB) has seen no adverse events during its non-clinical studies of EmtinB.
PharmAust (ASX:PAA) - Chief Scientific Officer, Dr Richard Mollard

" PharmAust (ASX:PAA) identifies optimal MPL dose for canine cancer

Clinical-stage biotech company PharmAust (PAA) has identified the optimum monepantel (MPL) drug plasma range for dogs with B-cell lymphoma.
Alcidion Group (ASX:ALC) - Group Managing Director, Kate Quirke

" Alcidion Group (ASX:ALC) extends contract with Sydney Local Health District

Alcidion Group (ALC) has expanded the use of its remote patient monitoring platform, Miya Precision, with the Sydney Local Health District (LHD).